News:  Plus Therapeutics Announces Plans for Treating Pediatric Brain Cancer

Pediatric Brain Cancer:
U.S. Phase 1 Clinical Trial

 

Not Yet Recruiting

Pediatric Brain
Cancer:  U.S. Phase
1 Clinical Trial

 

Not Yet Recruiting

Pediatric
Brain
Cancer:
U.S. Phase
1 Clinical
Trial

 

Not Yet Recruiting

Trial Information

Cancer is the leading cause of death by disease among children in the U.S.  Brain and spinal cord tumors are the 2nd most common cancers in children, accounting for ~26% of childhood cancers.

Plus Therapeutics is developing the Rhenium (186Re) Obisbemeda radiotherapeutic for the treatment of rare, frequently fast-growing pediatric brain and spinal cord tumors with a poor prognosis – ependymoma and high-grade glioma (HGG).  The ReSPECT-PBC (Pediatric Brain Cancer) U.S. Phase 1 Clinical Trial is planned to start in 2023.

“Children with brain tumors have limited options & 186RNL delivered with a minimally invasive procedure could be an important new potential option for these patients.”

Michael G. DeCuypere, MD, PhD, FAANS

Northwestern University Feinberg School of Medicine

Principal Investigators

There is a physician who is responsible for the scientific and technical direction of the clinical trial at each location.

Ashley S. Plant, M.D.

Lurie Children’s Hospital of Chicago

SPECIALTIES:  CANCER & BLOOD DISORDERS

Ashley S. Plant, M.D. is an attending physician in neuro-oncology at Ann and Robert H. Lurie Children’s Hospital of Chicago and is an Assistant Professor of Pediatrics at Northwestern University. Dr. Plant received her medical degree from Stanford University School of Medicine. She completed her pediatrics residency at University of California, Los Angeles and her pediatric hematology/oncology fellowship at Dana Farber Cancer Institute/Boston Children’s Hospital. She completed additional training in neuro-oncology at Dana Farber Cancer Institute. Her research focus includes immunotherapy and the immune microenvironment as well as early phase clinical trial design for pediatric brain tumors.

Trial Locations

Please visit this website regularly for updates as new locations are added.

Lurie Children’s Hospital

Chicago, Illinois

What Can You Do Next?

Participating in a clinical trial is an important decision.  If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.

Request Information

7 + 2 =

News

 

November 19, 2022

Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

In November 2022, Plus Therapeutics, in collaboration with Lurie Children’s Hospital investigators, anticipates filing an Investigational New Drug (IND) application for a first-in-child Phase 1/2a clinical trial to determine the maximum tolerated dose, safety, tolerability and early efficacy of rhenium (186Re) obisbemeda in supratentorial recurrent or progressive pediatric ependymoma and high-grade glioma (HGG) in up to 24 patients initially. These plans were presented in a poster titled, “A two-part, Phase 1 study of Rhenium-186 NanoLiposome (186RNL) delivered by convection enhanced delivery (CED) for recurrent or progressive childhood ependymoma and high-grade glioma (HGG) [CTNI-19]”.

August 21, 2021

Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer

June 10, 2021

Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference